Abicipar pegol for neovascular age-related macular degeneration

Keyphrases

• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Abicipar Pegol 100%
• Inflammation 66%
• Treatment Burden 66%
• DARPin 66%
• Abicipar 66%
• Clinical Trials 33%
• Standard of Care 33%
• Progressive Disease 33%
• Potential Therapeutics 33%
• Dose Rate 33%
• High Affinity 33%
• Intravitreal Injection 33%
• Literature Search 33%
• PubMed 33%
• Expert Opinion 33%
• Area Cover 33%
• Visual Gain 33%
• Protein Molecules 33%
• Molar Concentration 33%
• Long-acting Agents 33%
• Chronic Progressive 33%
• Ranibizumab Injection 33%
• Intravitreal Anti-vascular Endothelial Growth Factor Injection 33%
• Manufacturing Process 33%
• Stable Vision 33%
• Antibody Fragment 33%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 33%
• Ocular Inflammation 33%
• Cedar 33%
• Matrix-assisted Pulsed Laser Evaporation (MAPLE) 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammation 100%
• Wet Macular Degeneration 100%
• Abicipar pegol 100%
• Vasculotropin 66%
• Ankyrin 66%
• Clinical Trial 33%
• Diseases 33%
• Intravitreal Administration 33%
• Ranibizumab 33%